Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France.
作者信息
Lefèvre Benjamin, Tondeur Laura, Madec Yoann, Grant Rebecca, Lina Bruno, van der Werf Sylvie, Rabaud Christian, Fontanet Arnaud
机构信息
Infectious and Tropical Diseases, CHRU-Nancy, Université de Lorraine, Nancy, France.
APEMAC, Université de Lorraine, Nancy, France.
出版信息
Lancet Healthy Longev. 2021 Nov;2(11):e685-e687. doi: 10.1016/S2666-7568(21)00230-0. Epub 2021 Sep 22.
Abstract
摘要
相似文献
1
Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France.法国长期护理机构中新冠病毒变异株β和BNT162b2疫苗的有效性
Lancet Healthy Longev. 2021 Nov;2(11):e685-e687. doi: 10.1016/S2666-7568(21)00230-0. Epub 2021 Sep 22.
2
Effectiveness of mRNA BNT162b2 COVID-19 vaccine against SARS-CoV-2 Delta variant among elderly residents from a long-term care facility, South of France, May 2021.mRNA BNT162b2 新冠疫苗在法国南部长期护理机构老年居民中预防 SARS-CoV-2 德尔塔变异株的有效性，2021 年 5 月。
Eur Rev Med Pharmacol Sci. 2022 Apr;26(7):2586-2591. doi: 10.26355/eurrev_202204_28496.
3
Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents.BNT162b2疫苗对青少年Delta变异株的有效性
N Engl J Med. 2021 Nov 25;385(22):2101-2103. doi: 10.1056/NEJMc2114290. Epub 2021 Oct 20.
4
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.长期护理机构中未感染 SARS-CoV-2 的居民在接种 BNT162b2 疫苗 3 个月后体液反应减弱。
Age Ageing. 2022 May 1;51(5). doi: 10.1093/ageing/afac101.
5
Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.2021 年 8 月至 10 月，BNT162b2 疫苗第三剂接种与长期护理机构居民 SARS-CoV-2 感染、COVID-19 相关住院和死亡的相关性。
JAMA Netw Open. 2022 Jul 1;5(7):e2219940. doi: 10.1001/jamanetworkopen.2022.19940.
6
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.以色列卫生保健工作者中，第三剂 BNT162b2 疫苗接种与 SARS-CoV-2 感染发生率的关联。
JAMA. 2022 Jan 25;327(4):341-349. doi: 10.1001/jama.2021.23641.
7
Evaluation of BNT162b2 Vaccine Effectiveness in Galicia, Northwest Spain.西班牙西北部加利西亚地区评估 BNT162b2 疫苗的有效性。
Int J Environ Res Public Health. 2022 Mar 29;19(7):4039. doi: 10.3390/ijerph19074039.
8
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.BNT162b2和mRNA-1273新冠疫苗在卡塔尔针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔变种的有效性
Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 2.
9
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
10
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak in a Long-term Care Facility After Vaccination With BNT162b2.接种BNT162b2疫苗后长期护理机构中出现严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫情。
Clin Infect Dis. 2021 Dec 6;73(11):2147-2148. doi: 10.1093/cid/ciab299.
引用本文的文献
1
BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.新加坡儿童和青少年中 BNT162b2 疫苗对奥密克戎的保护作用以及既往感染变异株和接种顺序的影响：一项基于人群的队列研究。
Lancet Child Adolesc Health. 2023 Jul;7(7):463-470. doi: 10.1016/S2352-4642(23)00101-3. Epub 2023 May 15.
2
SARS-CoV-2 in Nursing Homes: Analysis of Routine Surveillance Data in Four European Countries.养老院中的新型冠状病毒 2：四个欧洲国家常规监测数据分析
Aging Dis. 2023 Apr 1;14(2):325-330. doi: 10.14336/AD.2022.0820.
3
Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies.在动物研究中，一种基于刺突蛋白亚单位的 COVID-19 疫苗具有广泛的针对各种 SARS-CoV-2 变体的免疫原性。
PLoS One. 2023 Mar 24;18(3):e0283473. doi: 10.1371/journal.pone.0283473. eCollection 2023.
4
Covid-19: virology, variants, and vaccines.新型冠状病毒肺炎：病毒学、变种与疫苗
BMJ Med. 2022 Apr 1;1(1):e000040. doi: 10.1136/bmjmed-2021-000040. eCollection 2022.
5
A genetically engineered, stem-cell-derived cellular vaccine.一种基因工程、干细胞衍生的细胞疫苗。
Cell Rep Med. 2022 Dec 20;3(12):100843. doi: 10.1016/j.xcrm.2022.100843. Epub 2022 Dec 7.
6
Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States.比较 SARS-CoV-2 疫苗有效性评估中的病例对照和综合征对照，以预防美国 COVID-19 住院治疗。
Vaccine. 2022 Nov 15;40(48):6979-6986. doi: 10.1016/j.vaccine.2022.10.034. Epub 2022 Oct 24.
7
Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021.疫苗对 2021 年 4 月美国华盛顿护理机构居民中 SARS-CoV-2 变体 P.1 的有效性。
Emerg Infect Dis. 2022 Nov;28(11):2338-2341. doi: 10.3201/eid2811.221043. Epub 2022 Sep 28.
8
COVID-19 in French nursing homes during the second pandemic wave: a mixed-methods cross-sectional study.法国养老院内的 COVID-19 在第二波疫情期间：一项混合方法的横断面研究。
BMJ Open. 2022 Sep 20;12(9):e060276. doi: 10.1136/bmjopen-2021-060276.
9
Heterologous immunity induced by 1 generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine.由 1 代 COVID-19 疫苗诱导的异源免疫及其在开发泛冠状病毒疫苗中的作用。
Front Immunol. 2022 Aug 15;13:952229. doi: 10.3389/fimmu.2022.952229. eCollection 2022.
10
Epidemiological assessment of SARS-CoV-2 reinfection.SARS-CoV-2 再感染的流行病学评估。
Int J Infect Dis. 2022 Oct;123:9-16. doi: 10.1016/j.ijid.2022.07.075. Epub 2022 Aug 2.
本文引用的文献
1
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France.原始毒株、B.1.1.7毒株以及B.1.351/P.1 新冠病毒谱系对两剂新冠mRNA疫苗有效性的影响：法国一项全国性病例对照研究的结果
Lancet Reg Health Eur. 2021 Sep;8:100171. doi: 10.1016/j.lanepe.2021.100171. Epub 2021 Jul 13.
2
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.德尔塔变异株对抗体中和的敏感性降低。
Nature. 2021 Aug;596(7871):276-280. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.
3
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants.BNT162b2新冠疫苗对B.1.1.7和B.1.351变异株的有效性
N Engl J Med. 2021 Jul 8;385(2):187-189. doi: 10.1056/NEJMc2104974. Epub 2021 May 5.
4
Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination.年龄相关的对辉瑞/生物科技 BNT162b2 冠状病毒病 2019 疫苗接种的免疫反应。
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072. doi: 10.1093/cid/ciab381.
5
Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019.血清对严重急性呼吸综合征冠状病毒 2 和多种变异株的中和活性在因 2019 年冠状病毒病住院 6 个月后
Clin Infect Dis. 2021 Sep 15;73(6):e1337-e1344. doi: 10.1093/cid/ciab308.
6
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2.新型冠状病毒感染及一剂BNT162b2疫苗接种后对变异株的中和反应
N Engl J Med. 2021 Jun 24;384(25):2453-2454. doi: 10.1056/NEJMc2104036. Epub 2021 Apr 7.
7
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.SARS-CoV-2 501Y.V2 逃避恢复期血浆中和作用。
Nature. 2021 May;593(7857):142-146. doi: 10.1038/s41586-021-03471-w. Epub 2021 Mar 29.
8
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.传染性 SARS-CoV-2 B.1.1.7 和 B.1.351 变体对中和抗体的敏感性。
Nat Med. 2021 May;27(5):917-924. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.
9
Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021.2021 年 1 月至 3 月法国对 SARS-CoV-2 谱系 20I/501Y.V1（B.1.1.7，202012/01 关注变体）的扩散和可能扩大的早期评估。
Euro Surveill. 2021 Mar;26(9). doi: 10.2807/1560-7917.ES.2021.26.9.2100133.
Zotero 插件